

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Hashime KANAZAWA et al.

Mail Stop: PCT

Serial No. 10/588,725

Attorney Docket No. 2006 1265A

Filed August 8, 2006

COMBINED PHARMACEUTICAL COMPOSITION [Corresponding to PCT/JP05/001801 Filed February 8, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the reference listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

[X]	each U.S. Patent and U.S. Patent application publication;
[]	each reference previously cited in the international application PCT/; and/or
0	each reference previously cited in prior parent application Serial No.
[X] TI	his Information Disclosure Statement is submitted:

la.

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b.	Π	This	Inform	nation	Disclosure	Statement	is submitted
-----	---	------	--------	--------	------------	-----------	--------------

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4.	For each non-English language reference listed on the attached form PTO-1449, reference is made to:								
	a.	[]	a full or partial English language translation submitted herewith,						
	b.		a foreign patent office search report (in the English language) submitted herewith,						
	c.		the concise explanation contained in the specification of the present application at page,						
	d.	[]	the concise explanation set forth in the attached English language abstract,						
	e.	[]	the concise explanation set forth below or on a separate sheet attached to the reference:						
5.	[]	A for	eign patent office search report	t citing one or more of the references is enclosed.					
			R	espectfully submitted,					
			H	Iashime KANAZAWA et al.					
			В	Warren M. Cheek, Ir. Registration No. 33,367 Attorney for Applicants					
WMC			C 20004 1021						
w asn	mgu	יו, ע.וי	C. 20006-1021						

Telephone (202) 721-8200 Facsimile (202) 721-8250 September 13, 2006

Sheet 1 of 1	` .		INFORMA	TION DISCLOS	SURE STATEMENT	_		RIPE	
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				ATTY DOCKET NO. 2006_1265A SEP 1 3			2EL 1 3 500	8	
				APPLICANT Hashime KANAZAWA et al.					
(Use several sheets if necessary) Date Submitted to PTO: September 13, 2006				FILING DATE GROUP					
- Date Out	- Intitod t	or ro. deptember 13, 2		August 8,	· · · · · · · · · · · · · · · · · · ·				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE			CLASS	SUBCLASS FILING DATE APPROPRIA		
	AA								
	АВ								_
	AC								
	AD								
	AE								
	AF								
_	AG								
	АН					· · · · · · · · · · · · · · · · · · ·		, ···•	
	Al							· · · · ·	
I			FORE	IGN PATENT	DOCUMENTS	······	<u>.</u>	<u> </u>	
		DOCUMENT NUMBER	DATE	cc	DUNTRY	CLASS	SUBCLASS	TRANSLA YES	TION NO
	AJ								
	AK								
	AL								
	АМ								
	AN								
		OTHER	DOCUMENT(S) (I	ncluding Autho	or, Title, Date, Pertinent Pa	ges, Etc.)			
	AO	Edited by Chikako TANAKA, Ryuichi KATO "NEW Yakurigaku (revised 3 rd edition)", Nankodo Co., Ltd., New Pharmacology, November 25, 1996 (25.11.96), pages 403 to 405, 504 to 506, full text (11 pages of English translation).							
	AP								
	AQ	,	·· ···		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		<u></u>		
EXAMINER					DATE CONSIDERED				